Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans by Li, H et al.
Title
Myocardial ischaemia reperfusion injury: the challenge of
translating ischaemic and anaesthetic protection from animal
models to humans
Author(s) Xia, Z; Li, H; Irwin, MG
Citation British Journal of Anaesthesia, 2016, v. 117 n. Suppl. 2, p. ii44-ii62
Issued Date 2016
URL http://hdl.handle.net/10722/229096
Rights
This is an electronic version of an article published in British
Journal of Anaesthesia. The definitive publisher-authenticated
version British Journal of Anaesthesia, 2016, v. 117 n. Suppl. 2,
p. ii44-ii62 is available online at:
http://bja.oxfordjournals.org/content/117/suppl_2/ii44; This work
is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License.
R EV I EW ART I C L E
Myocardial ischaemia reperfusion injury: the challenge
of translating ischaemic and anaesthetic protection
from animal models to humans
Z. Xia1,2,*, H. Li1 and M. G. Irwin1,2,*
1Department of Anaesthesiology, and 2Research Centre of Heart, Brian, Hormone and Healthy Aging,
The University of Hong Kong, Hong Kong SAR, China
*Corresponding author. E-mail: mgirwin@hku.hk (M.G.I.); E-mail: zyxia@hku.hk (Z.X.)
Abstract
Myocardial ischaemia reperfusion injury is the leading cause of death in patients with cardiovascular disease. Interventions
such as ischaemic pre and postconditioning protect against myocardial ischaemia reperfusion injury. Certain anaesthesia
drugs and opioids can produce the same effects, which led to an initial ﬂurry of excitement given the extensive use of these
drugs in surgery. Theunderlyingmechanismshave since been extensively studied in experimental animalmodels but attempts
to translate these ﬁndings to clinical settings have resulted in contradictory results. There are a number of reasons for this such
as dose response, the intensity of the ischaemic stimulus applied, the duration of ischaemia and lost or diminished
cardioprotection in common co-morbidities such as diabetes and senescence. This review focuses on current knowledge
regardingmyocardial ischaemia reperfusion injury and cardioprotective interventions both in experimental animal studies and
in clinical trials.
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The recent VISION (The Vascular events In non-cardiac Surgery
patIents cOhort evaluatioN) study1 found that 8% of patients
more than 45 yr of age suffered myocardial injury, based on
troponin assay, after non-cardiac surgery, of which 84.2% were
asymptomatic. This ﬁnding was signiﬁcant because, amongst
these, one in 10 died within 30 days. Ischaemic heart disease
(IHD) is also one of the leading causes of death in economically
developed countries worldwide. Increasing attention has been
paid to the development of interventions to re-establish blood
perfusion to ischaemic myocardium, to salvage tissue and pro-
tect against paradoxical reperfusion injury.2 This also decreases
the risk of post-ischaemic complications such as heart failure
and arrhythmia.2 Despite improvements in therapeutic strat-
egies such as angioplasty, thrombolysis, percutaneous coronary
intervention and coronary artery bypass surgery, recent studies
indicate that post-ischaemic 30 day mortality and morbidity
(about 8.5% after angioplasty and about 14% with thrombolysis)
remains signiﬁcant.3 The incident rate of IHD andpost-ischaemic
complications are signiﬁcantly increased in patients with co-
morbidities such as diabetes4 and/or hypertension. To make
things worse, patients with diabetes are not responsive to cardi-
oprotective strategies such as ischaemic preconditioning (IPC),5 6
postconditioning (IPo),7 and anaesthetic conditioning (APC)8 that
are otherwise effective in non-diabetic subjects. This highlights
the need to determine why hearts in patients with co-morbid-
ities, in particular those with diabetes are susceptible to ischae-
mia and yet not sensitive to cardioprotective interventions. The
answer to this question may facilitate the development of
novel cardioprotective strategies that may also be applicable in
other patients, such as the elderly.
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Mechanism of ischaemia reperfusion injury
Myocardial infarction isusually causedby rupture of anatheroma-
tous plaque in a coronary artery. Re-establishment of coronary
blood ﬂow (reperfusion) is mandatory to salvage the ischaemic
myocardium but this is accompanied by dramatic changes in
mitochondrial permeability transition pore (mPTP) opening, gen-
eration of reactive oxygen species (ROS), bioavailability of nitric
oxide (NO), intracellular distribution of Ca2+ andNa+, andpH. Para-
doxically, reperfusion itself can actually cause cardiomyocyte
death and subsequent irreversible myocardial injury, a phenom-
enon termed ‘ischaemia reperfusion injury (IRI)’.9 (Fig. 1).
Mitochondrial dysfunction during myocardial ischaemia
reperfusion
In order to meet the high energy demand for both contractility
and diastolic relaxation, the heart needs a continuous energy
supply, which depends on the synthesis of adenosine triphos-
phate (ATP). Approximately 95% of this ATP comes from mito-
chondrial oxidative phosphorylation.10 Thus, mitochondrial
function has been considered as a key factor in the aetiology of
myocardial ischaemia, a state of energy deﬁcit in the heart. Mito-
chondrial dysfunction affects cell viability through a wide array
of events including reduction or loss of ATP synthesis, increase
in ATP hydrolysis,11 impairment in ionic homeostasis,12 and for-
mation of ROS.13 All these suggest a critical role of mitochondria
in myocardial IRI and, as such, mitochondria may act as critical
triggers,mediators and effectors for protective strategies directed
against myocardial IRI.
Under physiological conditions, themitochondrial innermem-
brane is impermeable (except for a few selected metabolites and
ions). However, under pathological conditions such as myocardial
ischaemia, oxygenandnutrient deprivation causesanon-selective
opening of the inner mPTP, resulting in depolarization and
uncoupling/impairment of oxidative phosphorylation.14 This not
only leads to ATP depletion but also causes the breakdown of any
available ATP, which subsequently induces the hydrolysis of ATP
and the enhancement of mitochondrial inorganic phosphate.12
On the other hand, during ischaemia (in the absence of oxygen)
cellular metabolism switches to anaerobic glycolysis and the sub-
sequent accumulation of lactate reduces intracellular pH (lower
than 7.0).15 Depletion of ATP and acidosis impede the ability of
the Na+/K+ antiporter to remove excess Na+ caused by the increase
of intracellular proton accumulation-induced activation of Na+/H+
ion exchanger, resulting in intracellular Ca2+ overload and mito-
chondrial swelling.11 Inﬂux of Ca2+ into the mitochondria and an
increase in ROS production both favour mPTP opening, but the as-
sociated acidosis obstructs its opening. After reperfusion, a quick
pH correction exacerbates the opening of the mPTP within a few
min.16 17 This, in turn, leads to an abrupt increase in ﬂow of accu-
mulated electrons and an associated increase in electron leak
which, together with the damaged electron transport chain, not
only damages mitochondria but also promotes a burst production
of superoxide anion and other ROS,18 19 eventually causing cell
death (Fig. 1). Therefore, preventingmPTPopeningat the timeof re-
perfusion (mPTP remains closed during ischaemia) or timely re-
moval of damaged mitochondria would serve as promising
therapeutic avenues to protect the heart frommyocardial IRI.
It has been shown that direct inhibition of mPTP opening by
cyclosporine A, attenuated myocardial injury after reperfusion
both in experimental studies in small20 and large animals21 and
in patients with acute ST-elevation myocardial infarction.22
Treatments targeting inhibition of mPTP have been proved to
be cardioprotective and are currently being evaluated for clinical
use.23 24 As such, the mPTP provides an important therapeutic
target for preventing lethal myocardial IRI. However, because of
the complexity of mitochondrial metabolism and the fact that
most experimental studies have been performed on isolated
mitochondria which lack cellular context, further investigation
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Fig 1 Schematic of proposed mechanism of myocardial ischaemia reperfusion injury. Myocardial ischaemia reperfusion increases mitochondrial permeability
transition pore (mPTP) opening which elevates reactive oxygen species (ROS) generation, decreases nitric oxide (NO) bioavailability, and disrupts intracellular
distribution of Ca2+, Na+ and pH, resulting in cardiomyocyte death and subsequent irreversible myocardial injury.
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is needed to reveal thewhole picture of the role andmechanisms
ofmPTP inmyocardial IRI and its application as a therapeutic tar-
get for cardioprotection.
Overproduction of reactive oxygen species during
myocardial ischaemia reperfusion
ROS such as superoxide anion, hydrogen peroxide, and hydroxyl
radicals are generated as by-products of cellular metabolism.
Under physiological conditions, small amounts of ROS are beneﬁ-
cial as they participate in normal cellular signaling18 and serve as
an important mediator in the cardioprotection of IPC.25 However,
under stress such as myocardial ischaemia reperfusion, after pro-
longed ischaemia, re-introduction of bloodﬂow (reperfusion) leads
to a massive burst of ROS production from damaged mitochon-
dria.11This exceeds thedefensive capacityof the cells (e.g. catalase,
glutathione peroxidase, and superoxide dismutase) and is detri-
mental to cardiomyocytes. Productionof large quantities of ROS re-
sults in overloading of Ca2+,2 10 breakdown of critical proteins as a
result of protein oxidation,26 generationof peroxynitrite (ONOO-),27
disruption of cholesterol containingmembranes as a result of lipid
peroxidation,28 opening of the mPTP,29 and reduction of nitric
oxide availability.30 This phenomenon is termed oxidative stress
and ultimately causes cell death.
As increased generation of ROS during the ﬁrst min of reperfu-
sion is a major contributor to the pathogenic mechanisms under-
lying myocardial IRI, antioxidant therapy has been considered an
appropriate option of preventive treatment. However, results from
experimental and clinical studies are inconsistent. We and others
have shown that antioxidant treatment with N-acetylcysteine
and/or allopurinol, attenuates post-ischaemic myocardial injury
in a rat model of myocardial IRI27 31 and in patients undergoing
coronary artery bypass surgery.32 However, others did not observe
a beneﬁcial antioxidant effect in patientswith vascular disease,33 34
and long-term antioxidant (vitamin E) supplementation does not
prevent major cardiovascular events and may even increase the
risk of heart failure.35 A possible explanation for this contradic-
tionmay be the difference in timing and the choice of an antioxi-
dant that targets speciﬁc ROS. It may also be because of the
inability of the antioxidant to actually enter the cell.36 Given
that mitochondria are considered as the primary site of ROS gen-
eration, discovery of mitochondrial-speciﬁc antioxidants37 38
may providemore effective therapy in combatingmyocardial IRI.
Reduction of nitric oxide bioavailable during myocardial
ischaemia reperfusion
Nitric oxide (NO) is produced by NO synthases [NOS, with three
isoforms respectively called endothelial (eNOS), neuronal
(nNOS), and inducible NOS (iNOS)] through converting L-arginine
to L-citruline in the presence of oxygen. NO is a critical signalling
molecule in the cardiovascular system, acting as one of the most
important defence mechanisms against myocardial IRI and as a
mediator of cardioprotective interventions such as IPC and IPo.
NO exerts its cardioprotective effect via distinct mechanisms: (1)
activation of NO-sensitive guanylyl cyclase,39 (2) inhibition of
mitochondrial Ca2+ inﬂux40 41 and activation of themitochondrial
KATP channel,
42 (3) activation of cGMP,43 (4) enhancement of cy-
clooxygenase-2,44 and (5) abrogation of ONOO-mediated lipid rad-
ical chain propagation.45 In the setting of prolonged myocardial
ischaemia, the activity/activation of NOS (primarily eNOS and
nNOS) is reduced concomitant with the reduced supply of oxygen
that is required for the synthesis of NO from NOS. Thus, depriv-
ation of oxygen during ischaemia leads to reduced or diminished
NO release. Hence, enhancement of NOS activity/activation and
NO bioavailability has been shown to be cardioprotective. Indeed,
eNOS knockout exacerbates post-ischaemic myocardial injury in
mice subjected to myocardial IRI,46 while overexpression of eNOS
improves post-ischaemia cardiac functional recovery.47 Also, en-
hancing NO bioavailability by exogenous application of NOS and
L-arginine, attenuates ischaemia reperfusion-induced microcircu-
latory alterations48 and post-ischaemic infarction.49 However, high
concentration of NO in the presence of increased superoxide anion
productionmay be detrimental as a consequence of increased for-
mation of peroxynitrite (ONOO-), which exacerbates post-ischae-
mic myocardial injury. Interestingly, treatment with a NO donor
in combination with an antioxidant, has been shown to reduce
post-ischaemic myocardial infarct size and improve contractile
function in the isolated rat heart model,49 indicating that main-
taining a physiological concentration of NO is important for NO
to confer its cardioprotective effects. Taken together, the cardio-
protective effects of NO depend on its concentration/production,
subcellular localization, and its bioavailability. Thus, further stud-
ies are needed to better understand themetabolism and dynamics
of NOduringmyocardial IRI, in order to liberate the correct amount
of NO in the correct place and at the correct time, under varying
pathological conditions.
Other mechanisms of pre- and post-conditioning
cardioprotection
Manyof the endogenous signalling pathways that participate in an-
aesthetic-mediated cardioprotection have been identiﬁed. Mito-
chondrial oxidative phosphorylation is the main source of ATP
production in the heart, providing the steady supply of ATP required
to sustain cardiac contraction, and, as such, mitochondria have
been the main focus in cardioprotection. Indeed, signalling path-
ways targeting cell factions other than mitochondria, such as the
nucleus andmembrane, also play important roles. For instance, se-
voﬂurane postconditioning by activating Nrf2, upregulated antioxi-
dant genes in the nucleus, resulting in attenuation of myocardial
ischaemia reperfusion injury.50 The integrity and functionality of
the cell membrane has also been proposed51 tomediate the cardio-
protection of anaesthetics such as sevoﬂurane52 and isoﬂurane.53
Sevoﬂurane preconditioning has also been shown to confer delayed
cardioprotection via inhibiting Beclin 1-mediated autophagic cell
death, in cardiac myocytes subjected to hypoxia/reoxygenation
injury after brief exposure to sevoﬂurane 24 h before inducing
hypoxia,54 and is likely to involve both mitochondrial and non-
mitochondrial mechanisms. Further in-depth investigation is
needed to decipher their relative importance, timing of activation,
and interactions, and to providemore insight into themechanisms
of volatile anaesthetic cardioprotection.
Protection against myocardial ischaemia
reperfusion injury
Ischaemic conditioning
Ischaemic conditioning is achieved by intermittent occlusion of a
coronary vessel either locally or remotely, by inducing reversible
ischaemia of a distant organ (remote ischaemic conditioning),
and limits myocardial infarct size. Ischaemic conditioning can
be applied at different time points: before the induction of a per-
iod of prolonged ischaemia (IPC, ischaemic preconditioning) or
immediately at the onset of reperfusion after prolonged ischae-
mia (IPo, ischaemic postconditioning). All these cardioprotective
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strategies confer their effects by activating endogenous pro-sur-
vival signalling pathways.
Ischaemic preconditioning
Ischaemic preconditioning (IPC) was ﬁrst described by Murry and
co-workers in a dog model.55 The ﬁrst clinical evidence was pro-
vided by inducing several cycles of transient non-lethal ischae-
mia, using an aortic cross-clamp interspersed with reperfusion.
This reduced post-ischaemic myocardial troponin T release and
ATP depletion in patients undergoing cardiac bypass surgery.56
The protective effect of IPC is biphasic. The ‘ﬁrst window’ or
early phase arises immediately after ischaemic stress and lasts
for two to threeh. The ‘secondwindow’or latephase cardioprotec-
tion occurs 12–24 h after initial preconditioning and lasts for up to
48–72 h.57–59 Ischaemic preconditioning confers its early phase
protection through the modiﬁcation of existing prosurvival pro-
teins in the heart, to protect against myocardial infarction, but it
has no signiﬁcant effect on limiting the degree of contractile dys-
function. The late phase of ischaemic preconditioning protection,
is a result of the production of cytoprotective proteins in themyo-
cardium and protects the heart from cardiomyocyte death while
improving post-ischaemic cardiac functional recovery.57 Thus,
the late phase of IPC cardioprotection ismore clinically applicable
for its more signiﬁcant protection and longer duration.
IPC confers cardioprotection by creating a cardiac ‘memory’
between the triggers and end-effectors in the signalling path-
ways in order to keep the heart in a ‘preconditioned’ state.60
Threemajor endogenous triggers of IPC are adenosine,61 bradyki-
nin,62 and opioids,63 all of them are classiﬁed as G coupled pro-
tein receptor dependent triggers. There are others including
ROS, the mitochondrial KATP channel and NO, which probably
trigger IPC through the activation of G coupled proteins64 and
protein kinases.65 After being stimulated by IPC, these triggers ac-
tivate their downstream mediators, among which are mainly
protein kinases, such as protein kinase C (PKC), Akt, tyrosine ki-
nase, and the mitogen activated protein kinase (MAPK). PKC was
one of the ﬁrst mediators of IPC to be identiﬁed.66 67 Gene knock-
out of PKC-ε cancels the cardioprotective effects of IPC in mice.68
However, in isolated ischaemic reperfused rat hearts, PKC-δ in-
hibition attenuates myocardial IRI, while PKC-ε activator (but
not PKC-δ activator) mimics IPC,69 supporting the notion that
PKC activation-mediated cardioprotection in IPC is isoform-spe-
ciﬁc. Further investigation is needed to provide a full picture of
the beneﬁcial or detrimental role of speciﬁc isoforms of PKC acti-
vation in the process of IPC. Numerous upstream activators (e.g.
PI3K-Akt,70 NO,71 and mitochondrial KATP channel
72) or down-
stream targets (Sarcolemmal KATP channel,
73 mitochondrial
KATP channel,
74 and p38MAPK75) of PKChave also been suggested
as IPC mediators. There are others that work in parallel with the
PKC pathway in IPC, including receptor tyrosine kinase, MEK1/2-
Erk1/2, the Jak-STAT pathways, GSK-3β, and ROS25 76 (Fig. 2).
The ultimate end-effectorof IPChasnot beendetermined, des-
pite extensive research. Themitochondrion is where most signal-
ling pathways governing IPC cardioprotection converge. The
opening of the mitochondrial KATP channel by IPC inhibits mito-
chondrial Ca2+ overload77 78 and attenuates myocardial IRI.
Other studies have shown that opening of the mitochondrial
KATP channel facilitates the generation of small amounts of ROS
and activates PKC, which in turn phosphorylates the mitochon-
drial KATP channel and keeps it in the opened state.
79 Inhibition
of mPTP opening has also been considered as the ﬁnal step in
the process of IPC. It has been shown that IPC may inhibit mPTP
opening through GSK-3β, eNOS, or via the reperfusion injury
salvage kinase (RISK) pathway80 81 (Fig. 2). Of note, there are also
other components that have been suggested as the end-effectors
of IPC, for instance, the cytoskeleton, gap-junctions, and the
Na+/H+ exchanger.80 Although IPC has been reported to be effect-
ive in both experimental and clinical studies, it needs to be per-
formed before the onset of prolonged myocardial ischaemia [i.e.
acute myocardial infarction (AMI)], which is neither predictable
nor feasible in most clinical situations. Therefore, the majority of
clinical investigations of IPC have been restricted to various car-
diovascular surgical procedures, including both vascular and car-
diac operations in which the ischaemia is predictable.
Ischaemic postconditioning
Recently, effort has focused onmodifying events occurring at the
time of myocardial reperfusion (ischaemic postconditioning,
IPo). Applying transient brief interruptions of reperfusion by is-
chaemic episodes to reducemyocardial injury, has higher clinical
potential than IPC as, for example, it can be performed aftermyo-
cardial infarction. IPowas ﬁrst demonstrated by Zhao and his co-
workers, in a rabbitmodel inwhich the investigators showed that
three repeated cycles of 30 s reperfusion followed by 30 s of occlu-
sion, after a prior 60min of coronary occlusion,markedly reduced
post-ischaemic myocardial infarct size and improved cardiac
functional recovery.82 IPo has also shown considerable promise
in clinical settings. In children undergoing corrective surgery
for tetralogy of fallot, IPo, achieved by two cycles of unclamping
the aorta for 30 s and then re-clamping the aorta for 30 s, reduced
the concentrations of CK-MB and troponin T (two reliable mar-
kers of myocardial injury) 2 h after surgery.83 This has also
been conﬁrmed in a number of clinical studies including cardiac
surgery for congenital heart disease,84 aortic valve replace-
ment,85 and percutaneous coronary intervention.86
It is now widely accepted that IPo confers its cardioprotective
effects via two intracellular pathways, the RISK pathway which
involves PI3K/Akt87 and the survival activating factor enhance-
ment pathway (SAFE), which involves Jak/STAT3.88 These path-
ways converge in the mitochondrion which is, obviously, an
integration point that is decisive for cardiomyocyte survival.14
As the experimental design of IPo mimics IPC and their cardi-
oprotective effects are similar, it is not surprising that IPo and IPC
share related cardioprotective signalling pathways. Indeed, ele-
ments of the RISK pathway, including PI3K, Akt, eNOS, and ad-
enosine receptors have also been shown to be involved in IPo
(Fig. 3). In isolated rat hearts, IPo stimulation reduced post-is-
chaemic infarct size with associated elevations in Akt, eNOS,
and p70S6K, while these beneﬁcial effects of IPo were abolished
by PI3K inhibition (either by LY294002 orwortmannin), indicating
the involvement of PI3K-Akt in IPo.89 In addition, pharmacologic-
al inhibition ofMEK1/2 abrogated IPo cardioprotection.90 Further-
more, other components of the RISK pathway, such as PKC,
Protein G, and p38 MAPK, are implicated in IPo cardioprotec-
tion.91 All these not only support the concept that cardioprotec-
tion of IPo shares a similar pathway (RISK) with IPC, but also
suggest that the RISK pathway could be a common pathway me-
diating cardioprotection. However, the involvement of the RISK
pathway in IPo has also been questioned. It was reported that
Erk1/2 but not PI3K-Akt was involved in IPo cardioprotection in
isolated rabbit hearts.92 Similarly, in in vivo porcine hearts, IPo
signiﬁcantly increased Akt and Erk1/2 phosphorylation but failed
to reduce post-ischaemic infarct size.93 The reason for these con-
troversial results is not clear, but a possible explanationwould be
the difference of the models and the protocols used in each ex-
periment. However, this may also suggest that IPo may confer
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cardioprotective effects through RISK-independent pathways. In-
deed, themore recently identiﬁed SAFE pathway has been shown
to be essential and can be activated independent of the RISK
pathway during IPo.88
The SAFE pathway is initiated by moderate elevation of tu-
mour necrosis factor (TNF)-α (a pro-inﬂammatory cytokine). The
cardioprotective effects of IPo were lost in TNF-α knockout
mice94 and exogenous TNF-α given at the onset of reperfusion
at a relative low dose canmimic the protective effects of IPo,94 in-
dicating that lowdoses of TNF-αmight serve as a triggerof IPo car-
dioprotection. Interestingly, administrationof TNF-α tomimic the
protective effects of IPo did not lead to the activation of Akt or
Erk1/2,95 while inhibition of Erk1/2 (by PD98059) or PI3K (by wort-
mannin) aborted the protective effects mediated by TNF-α when
applied at moderate dosage.94 These ﬁndings together with the
fact that Akt and Erk1/2 are components of theRISKpathway, pro-
vide evidence that downstream signalling of the SAFE pathway is
different from that of RISK and that the SAFE pathway can be acti-
vated independently in the setting of IPo. This concept has been
further supported by a study showing that neither Akt nor Erk1/
2 inhibition had signiﬁcant impact on IPo-induced reduction of
post-ischaemic infarct size inan in vivopigmyocardial IRImodel.88
After initiation by IPo, TNF-α binds to its receptor (TNFR2 in
myocardial IRI) and subsequently activates/phosphorylates signal
transducer and activator of transcription 3 (STAT3), a transcription
factor that has been shown to be an essential component of the
SAFE pathway in IPo. Once phosphorylated/activated, tyrosine-
phosphorylated STAT3 shuttles into the nucleus and initiates
stress-responsive gene transcription,96 97 serine-phosphorylated
STAT3 moves to mitochondria to regulate the mitochondrial re-
spiratory chain97 98 (Fig. 3). The importance of STAT3 activation
in the context of IPo has been demonstrated by both pharmaco-
logical inhibition99 and genetic deletion of STAT3.100 However, in-
formation regarding how IPo activates STAT3 is lacking. Moreover,
althoughSTAT3 is recognizedasa transcription factor, its activation
duringmyocardial IRI is much too rapid to assume that it works by
modulating gene transcription. Of note, it has been shown that the
RISK pathway is involved (but not essential) in IPo cardioprotection
andcross-talkexistsbetween theRISKandSAFEpathways.94AsAkt
cannot be phosphorylated in STAT3 knockout mice subjected to
IPC,101 it suggests that IPomay activate Akt via STAT3. IPo also acti-
vates STAT3 and increases itsmitochondrial expressionwhich sub-
sequently improves mitochondrial function in pig hearts.99 Given
thatmitochondrial STAT3co-localiseswithcyclophilinD, the target
of the mPTP inhibitor,102 and that mPTP also works as the end-ef-
fector of the RISK pathway, it follows that the SAFE and RISK path-
ways may converge at the mitochondria.
Remote ischaemic conditioning
Remote conditioning is a strategy whereby application of one or
more cycles of non-lethal ischaemia reperfusion to an organ or
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Fig 2 Schematic of proposed mechanism of ischaemic preconditioning cardioprotection. Ischaemic preconditioning exerts its cardioprotection through the
reperfusion injury salvage kinase (RISK) pathway that involves the activation of PI3K/Akt and MEK1/2 and, subsequently, activates PKA, eNOS, P70S6K and GSK-3β,
leading to a decrease in mitochondrial permeability transition pore (mPTP) opening and increase in the mitochondrial KATP (Mito KATP) channel opening which
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tissue, distant from the heart either before inducing prolonged is-
chaemia (remote ischaemic preconditioning, RIPC),103 or at the
onset of reperfusion (remote ischaemic postconditioning)104 pro-
tects against myocardial IRI. It was ﬁrst discovered in 1997 when
it was shown that repeated occlusions to a lower limb of rabbits
could attenuate myocardial infarct size after myocardial IRI, and
it was initially called ‘ischaemic preconditioning at a distance’.105
This simple and effective technique has subsequently been trans-
lated into clinical use. The ﬁrst clinical application of RIPC in hu-
mans was in 2006 in children undergoing cardiac surgery, where
RIPC (four 5 min cycles of lower limb ischaemia and reperfusion
using a blood pressure cuff ) signiﬁcantly reduced postoperative
troponin I release and inotrope requirement.106 However, negative
results have also been reported in cardiac bypass surgery.107 108
The possible explanation for this contradiction is not clear but
may be as a result of: (1) the use of anaesthetics such as sevoﬂur-
ane, opioids andpropofol, which can exert cardioprotective effects
themselves during cardiac bypass surgery; (2) differences in proto-
col and the timing of RIPC application; and (3) differences in
patient population and type of cardiac surgery. Thus, large
multi-centre, randomized, controlled clinical trials are needed to
conﬁrm the cardioprotective effects of RIPC. Indeed, a recent
large-scale trial has shown that RIPC is cardioprotective in pa-
tients undergoing elective CABG under ischaemic cardioplegic
arrest, in which medication with β-blockers, statins, angiotensin-
converting enzyme (ACE) inhibitors or angiotensin receptor
blockers (ARBs) was not interrupted for the CABG,109 while the
use of propofol was discontinued and diabetes was an exclusion
criterion.110 The efﬁcacy of RIPC mediated cardioprotection was
reﬂected in a reduction in serum troponin release, assessed by
the area under the curve values for serum troponin I frombaseline
to 72 h after surgery. Aortic cross-clamp timewas the major inde-
pendent variable that impacted efﬁcacy of RIPC.109 However, two
recent large-scale, prospective, randomized, sham-controlled
trials of RIPC in cardiac surgery with cardiopulmonary bypass,
have shown that RIPC was not effective when utilized in anaesthe-
tisedpatients immediately before surgery.111 112Thismaybe related
to the use of propofol, which induces cardioprotection via different
mitochondrially related molecular mechanisms.113 In contrast,
RIPC applied some time before surgery, increases myocardial sal-
vage-index in patients with acute myocardial infarction.114 Experi-
mentally, we and others have demonstrated that RIPC repeated for
three consecutive days, reduced myocardial infarction in rats with
chronic heart failure after myocardial infarction115 and in rats with
diabetes,116 117 twomaincofounders that impact the efﬁcacyofRIPC
cardioprotection. These suggest that RIPC initiated at a remote time
may allow the second-window of cardioprotection to develop and,
thereby, improve tolerance to ischaemia during cardiac surgery.
Thus, RIPC should not be abandoned but merits further clinical
trials concerning optimal timing of application.
Although RIPC currently has been extensively investigated,
the underlying mechanism remains unclear. Three inter-related
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events have been proposed: (1) RIPC-induced generation of
endogenous autocoids (e.g. encephalin, endorphin) in the
remote organ; (2) transmission of the protective signal from the
remote organ to the target organ; (3) events occurring in the tar-
get organ which ultimately confer the protective effect. Several
signalling mediators have been proposed to be involved in RIPC
including PKC, ROS, NO, Akt, Erk1/2, p38 MAPK, and STAT3,118
which are also the mediators of IPC and IPo. Further studies are
needed to identify potential triggers, clarify the downstream tar-
gets, and explore the end-effectors of RIPC.
Cardioprotection by anaesthetics
Application of certain drugs used in anaesthesia (e.g. isoﬂurane,
sevoﬂurane, propofol, and opioids) before or during the early
phase of reperfusion can also reduce myocardial ischaemia re-
perfusion injury, a phenomenon that is termed anaesthetic pre-
conditioning (APreC) and postconditioning (APoC), or collectively
referred to as anaesthetic pre- or post-conditioning (APC).
Mechanisms of APoC cardioprotection conferred
by volatile anaesthetics, propofol or opioids
Similar to ischaemic preconditioning, volatile anaesthetics and
opioids provide protection against myocardial IRI by stimulating
the generation of a small amount of ROS, which triggers and en-
hances the production of endogenous antioxidant enzymes and
activates mitochondrial KATP channels, limiting myocardial in-
farction.119 In contrast, propofol protects against myocardial IRI
mainly via its ROS scavenging properties, which enhances en-
dogenous cardiac antioxidant capacity and ultimately attenuates
myocardial IRI.120 Opioids play an important role in mammalian
hibernation. Endogenous and exogenous (e.g. remifentanil and
morphine) opioid agonists reduce myocardial oxidative stress
and Ca2+ overload and attenuate myocardial IRI both in animal
models and in patients undergoing cardiac surgery .121–124 Our
most recent study shows that remifentanil preconditioning con-
fers cardioprotection in rats, primarily via activation of JAK2/
STAT3 signalling, that can function independent of PI3K/Akt ac-
tivation.125 However, it should be noted that application of high
doses of opioid receptor agonists such as morphine126 and remi-
fentanil127 may cause signiﬁcant increases in ROS production in
the vascular endothelium and myocardium and subsequently
impair vascular endothelial function and exacerbate myocardial
ischaemia-reperfusion injury, although the doses of remifentanil
required to do this are much higher than those used clinically.
Major randomized clinical trials of anaesthetic conditioning
are listed in Table 1 which includes cardiac surgeries conducted
under either on-pump or off-pump conditions. It should bemen-
tioned that only the on-pump surgery provides typical ischae-
mia-reperfusion injury and that the duration of ischaemia time
may be one of the determinants of the effectiveness of condition-
ing protection.
Similarity in mechanism and potential advantages
of APC vs ischaemic conditioning
The concept of APC was evolved from IPC and IPo, and the me-
chanisms governing their cardioprotective effects are similar.
APC confers cardioprotectionmainly via the RISK and SAFE path-
ways (Fig. 4). APC activates the RISK pathway via a G-protein-
coupled cell surface receptor128 and activates the SAFE pathway
through the TNFα receptor,8 129 which all inhibit IRI-induced
mPTP opening and activate the opening of the KATP channel,
thereby protecting cardiomyocytes from IRI-induced cell death.
However, unlike IPC and IPo, anaesthetic application during
APC is to the whole body and it is possible, therefore, that APC
may also exert protection to other organs and other types of
cells rather than just cardiomyocytes. We have recently shown
that sevoﬂurane pre-treatment protects against TNF-α-induced
vascular endothelial dysfunction, through activation of the
eNOS/NO pathway and inhibition of NF-κB.130 Sevoﬂurane may
also protect against liver injury in patients undergoing cardiac
surgery.131–134 Exogenous opioids have also been shown to confer
systemic multi-organ protection. Remifentanil pre-treatment
ameliorated liver injury in rats subjected to hepatic ischaemia re-
perfusion135 and attenuated intestinal ischaemia reperfusion in-
jury in mice.136
Compared with IPC and IPo, APC is more clinical feasible as
anaesthetic agents are being used in surgery anyway. The bene-
ﬁcial effects of APC in a clinical setting was ﬁrst demonstrated by
Belhomme and colleagues137, who reported that isoﬂurane pre-
conditioning (5 min isoﬂurane exposure followed by 10 min
washout) reduced the release of cardiac troponin I (TnI) and cre-
atine kinase MB (CKMB), markers of cardiac injury, in patients
undergoing coronary artery bypass graft (CABG) surgery. Subse-
quently, the effects of APC in patients undergoing on-pump
and off-pump CABG surgery have been examined with conﬂict-
ing results. Exposure to isoﬂurane at 1–1.5 MAC end-tidal
throughout surgery, reduced postoperative plasma TnI and
CKMB release in patients undergoing CABG surgery with cardio-
pulmonary bypass.138 While in patients undergoing off-pump
CABG surgery, sevoﬂurane at 1MACprovided optimalmyocardial
protection as increasing sevoﬂurane concentration to 1.5 MAC
did not further attenuate myocardial injury and sevoﬂurane did
not confer cardioprotection when being used at 0.75 MAC.139
We also showed that treatment with propofol (120 mcg kg−1
min−1 for 10 min before the onset of CPB until 15 min after aortic
unclamping and then decreased to 60 mcg kg−1 min−1 until the
end of surgery) signiﬁcantly attenuated cardiac injury in patients
undergoing CABG, as compared with isoﬂurane or low dose pro-
pofol.140 Continuous administration of 1MACdesﬂurane induced
cardioprotection in patients undergoing CABG surgery evidenced
as reduced cardiac TnI release.141 However, administration of iso-
ﬂurane 1 MAC for 5 min followed by a 5 min washout before CPB,
did not reduce troponin I concentrations in patients undergoing
CABG with CPB.142 Similarly, a double-blind trial showed that
there was no difference among patients receiving propofol or se-
voﬂurane during surgery in terms of postoperative recovery in
the cardiac intensive care unit.143 Thus, currently it is premature
to draw a ﬁrm conclusion as to whether APC is beneﬁcial in the
clinical settings of CABG surgery, when patients are elderly
with co-morbidities such as diabetes and hypertension.
A recent meta-analysis of 2578 patients where on pump and
off pump patients were analysed separately, compared peak
postoperative cardiac TnI between volatile and i.v. anaesthesia.
Volatiles reduced postoperative peak serum cardiac TnI enzyme
concentrations by ∼8% on-pump with no difference seen in off
pump cardiac surgery.144 An accompanying editorial stated ‘So
how much longer do we need to keep repeating that the use of
a volatile anaesthetic regimen during on-pump coronary artery
surgery is associated with a lower post-operative cardiac tropo-
nin release comparedwith an intravenous anaesthetic regimen?’
and suggested that ‘authorsmust stop designing and performing
this type of study; ethical committees must stop approving such
trials and editors must stop publishing over and over again data
that simply conﬁrm what is already known’.145 However, all we
can discern from such data is that although volatile anaesthetics
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do seem to reduce cTnI concentrations in I/R injury, the clinical
signiﬁcance of cTnI reduction is unclear (although likely to be
good). I.V. anaesthesia in the abovemeta-analysiswas not homo-
geneous, with midazolam and even etomidate included in that
cohort, and, in our opinion, this does not mean that volatiles
are preferable to propofol in patients with cardiovascular disease
as both possess some, although different, cardioprotective prop-
erties. For example a large trial suggested that sevoﬂurane ap-
pears to be superior to propofol in patients with little or no
ischaemic heart disease, such as non-coronary artery bypass
graft (CABG) surgery and CABG surgery without severe preopera-
tive ischaemia, whereas propofol seems superior in patientswith
severe ischaemia, and/or cardiovascular instability, possibly be-
cause myocardial ischaemia has already preconditioned the
heart and propofol exerts it’s protection differently.146
Although experimental animal studies have consistently
shown effective cardioprotection and have identiﬁed the speciﬁc
cellular signalling involved, only a few studies have attempted to
identify and conﬁrm the speciﬁc cellular signalling of IPC, IPo,
and APC in humans. More importantly, attempts to translate
the ﬁndings regarding the mechanism and effectiveness of IPC,
IPo, and APC from experimental animals into the clinical setting
have largely failed. The reason for these failures might be: (1)
many of the patients have comorbidities such as diabetes,
aging, dyslipidemia, and hypertension which have been shown
to inﬂuence the protective effects of IPC, IPo, andAPC; (2) poor ex-
perimental design and no allowance for the use of concomitant
medication such as anaesthetics. Some of the confounding fac-
tors such as age, diabetes and myocardial remodelling that may
cause conﬂicting results in clinical trials have been discussed
elsewhere147 148 and summarized below.
Cardioprotection in diabetes and the impact
of diabetes on anaesthetic cardioprotection
Higher rates of cardiovascular disease andmortality after AMI are
observed in patients with diabetes. These patients are not only
vulnerable to myocardial IRI but also not sensitive to cardiopro-
tective strategies such as ischaemic conditioning and anaesthet-
ic conditioning, that are effective in non-diabetic animal models
of myocardial ischaemia/reperfusion or in non-diabetic patients
undergoing CABG surgery. Clinically, diabetes is considered as an
independent risk factor for cardiac injury during and after cardiac
surgery.149 Poorer recovery and higher mortality rates (two to
Anaesthetic conditioning (APC)
Cardiomyocytes Endothelial cells Other types of cells
SAFE
Other signaling
pathways
RISK
mPTP opening Mito KATP
Increase
Decrease
Nucleus
?
?
Cardioprotection
Metabolic dysfunction Apoptosis Oxidative/Nitrative stress
Fig 4 Schematic of proposed mechanism of myocardial anaesthetic conditioning cardioprotection. Anaesthetic conditioning protects the heart and other organs
against ischaemia reperfusion injury through the survivor activating factor enhancement (SAFE) and reperfusion injury salvage kinase (RISK) pathways, which,
subsequently, through mitochondrial-dependent and non-mitochondrial-dependent (nuclear or other) signalling pathways, decrease mitochondrial
permeability transition pore (mPTP) opening and increase mitochondrial KATP (Mito KATP) channel opening which attenuates ischaemia reperfusion injury.
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four-fold higher than in non-diabetic subjects) after acute myo-
cardial ischaemia/infarction (AMI) have also been reported.150
Infarct size was 30–70% larger after reperfusion therapy (either
thrombolytic therapy or percutaneous coronary intervention) in
diabetic than in non-diabetic patients,151 152 and worse short
and long-term progression after AMI was observed.153 154
Multiple factors have been proposed to contribute to the dis-
parate outcomes regarding the susceptibility of diabetic hearts to
myocardial IRI including: (1) the duration and the severity of the
diabetic status; (2) the experimental protocols (e.g. type of animal
species, severity of ischaemia and reperfusion); (3) the metabolic
proﬁles of diabetic subjects at the time the experiment was con-
ducted. Enhanced oxidative stress, which is mainly because of
the burst production of ROS and/or depleted endogenous antioxi-
dant system in diabetes, has been suggested as a major factor.155
Increased oxidative stress has been shown to increasemPTPopen-
ing156 and induce Ca2+ overload,157 factors that are attributable to
myocardial IRI as discussed earlier. More importantly, enhanced
oxidative stressmay also impair endogenous cardioprotective sig-
nalling, which not only increases post-ischaemic myocardial in-
jury in diabetic hearts but also diminishes or abolishes the
protective effects of cardioprotective interventions such as ischae-
mic conditioning.
With a few exceptions, the cardioprotection of IPC, IPo, and
APC has been shown to be compromised or even abolished in
the hearts of diabetics. The effectiveness of sevoﬂurane postcon-
ditioning in reducing post-ischaemic myocardial infarct size and
apoptosis in non-diabetic rats, was completely abrogated in strep-
tozotocin-induced diabetic rats and diabetes blockade of sevoﬂur-
ane postconditioning could not be restored by insulin,8 although it
could be restored by treatment with the antioxidant N-Acetylcys-
teine,whichattenuated or restoreddiabetes induced reductions in
cardiac p-STAT3 and adiponectin.158 Defects in the RISK and SAFE
pathways in diabetes have also been considered as a reason.159 160
However, the exact role and the mechanism of reduced cardiac
STAT3 activation in diabetes is not clear and needs further inves-
tigation, in order to facilitate the development of novel interven-
tions to restore myocardial sensitivity to IPo in diabetes.
Major cardiovascular co-morbidities that may affect
ischaemic or anaesthetic conditioning effects
Ischaemic, anaesthetic preconditioning and postconditioning, trig-
ger endogenous cardioprotective mechanisms that render the
heart more resistant to lethal ischaemia-reperfusion injury. How-
ever, in addition to diabetes and senescence as aforementioned,
certain major cardiovascular co-morbidities such as hyperlipid-
emia161 162 cardiomyocyte hypertrophy,163 hypertension,164 165
andmyocardial remodelling,166 andmany of their associatedmed-
ications (e.g. β-blockers, glibenclamide, glicazide) may interfere
with the mechanisms of conditioning cardioprotection, thereby
limiting the efﬁcacy of ischaemic or anaesthetic conditioning in
clinical settings. The exactmechanismsbywhich these co-morbid-
ities and medications interfere with conditioning cardioprotection
are not well understood. Glibenclamide abolishes the protective ef-
fect of mitochondrial KATP channel opening
167 and is one of the
worst drugs in this regard. Statins may actually increase the effect
of remote ischaemic conditioning168 (interestingly, in this trial,
smokers were more resistant to remote ischaemic conditioning).
A recent analysis of patients undergoing elective CABG with/with-
out remote ischaemic preconditioning found that β-blockers,
statins, ACE inhibitors, ARBs and intraoperative nitroglycerine
had no signiﬁcant impact on remote ischaemic conditioning-
induced cardioprotection.109 Further comprehensive analysis of
the cardioprotective genetic proﬁle in normal, protected, and in co-
morbid conditions in the context of conditioning stimuli, may lead
to identiﬁcationof novelmolecular targets for cardioprotection and
facilitation of clinical translation.
Summary and future perspectives
Anaesthetic and ischaemia-induced myocardial protective ef-
fects are fascinating phenomena that have been extensively
studied in various animal models with several mechanisms
now elucidated. Clinically, beneﬁcial effects, in terms of reduc-
tion in markers of cardiac injury, have also been demonstrated
in patients undergoing heart surgery. Remote ischaemic condi-
tioning, as a relatively simple and safe technique, may have par-
ticular clinical application (not only in protecting the heart but
manyother organs), however,many studies have been hampered
by small sample sizes and lack of hard and more long-term clin-
ical outcome data, with many relying on surrogate markers of
cardiac injury. Certain patients that are particularly vulnerable
to vascular complications (e.g. thosewith diabetes, hypertension
and senescence), are particularly resistant to cardiac condition-
ing of all forms and this may be further complicated by adjuvant
pharmacotherapy. Despite some ‘proof of concept’, large rando-
mized clinical trials are still needed to determine whether this
is just a healthy heart phenomenon or whether it’s something
thatwe can routinely use to protect our increasingly high-risk pa-
tients undergoing cardiac and vascular surgery.
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